

Abstracts to be presented at 41st Annual SABCS — December 4-8, 2018

WEDNESDAY December 5, 2018

Program Number: GS1-10

Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE. (NSABP B-50-I – NSABP Foundation).

Geyer Jr. CE, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Fischer HH, Redondo A, Jackisch C, Jacot W, Conlin AK, Schneeweiss A, Wapnir IL, Fasching PA, DiGiovanna MP, Wuelfing P, Arce-Salinas C, Crown JP, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, von Minckwitz G.

Presenter: Charles E. Geyer, Jr.

Session Title: General Session 1 — Hall 3

Session Date & Time: Wednesday 12-5-2018; 8:45 AM - 11:15 AM

Presentation Time: 11:00 AM

Program Number: OT1-09-01

Phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic response in patients with clinical/radiological complete response after neoadjuvant chemotherapy in order to explore the feasibility of breast-conserving surgery without surgery: NRG Oncology BR005.

Basik M, Costantino JP, De Los Santos JF, Umphrey HR, Julian TB, Mamounas EP, White JR, Lucas PC, Wagner JL, Tjoe JA, Thompson AM.

Presenter: Mark Basik

Session Title: Ongoing Trials - Neoadjuvant Chemotherapy Assessment

Location: Ongoing Trials Poster Session OT1 – Hall 1

Session Date & Time: Wednesday, 12-5-2018; 5:00 PM - 7:00 PM

THURSDAY December 6, 2018

Program Number: PD3-02

Incidence of late relapse in HER2-positive (HER2+) breast cancer patients receiving adjuvant trastuzumab: Combined analysis of NCCTG (Alliance) N9831 and NSABP (NRG) B31 trials.

Chumsri S, Li Z, Serie DJ, Mashadi-Hosseini A, Colon-Otero G, Song N, Pogue-Geile K, Gavin P, Paik S, Moreno-Aspitia A, Perez EA, Thompson EA.

Presenter: Saranya Chumsri

Session Title: Next Steps in HER2+ Targeted Therapy

Location: Spotlight Session 3 – Stars at Night Ballroom 1&2

Session Date & Time: Thursday, 12-6-2018; 7:00 AM -9:00 AM

THURSDAY December 6, 2018 con't

Program Number: PD3-04

Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease with initially diagnosed HER2+ breast cancer: NSABP FB-10. (NSABP Foundation)

Abraham J, Puhalla SL, Sikov WM, Montero AJ, Salkeni MA, Razaq WA, Beumer JH, Kiesel BF, Buyse ME, Adamson LM, Srinivasan A, Pogue-Geile KL, Allegra CJ, Nagy RJ, Jacobs SA.

Presenter: Jame Abraham

Session Title: Next Steps in HER2+ Targeted Therapy

Location: Spotlight Session 3 – Stars at Night Ballroom 1&2

Session Date & Time: Thursday, 12-6-2018; 7:00 AM - 9:00 AM

Program Number: GS3-02

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib. (NSABP FB-11 - NSABP Foundation)

Dowsett M, Jacobs S, Johnston S, Bliss J, Wheatley D, Holcombe C, Stein R, McIntosh S, Barry P, Dolling D, Snowdon C, Perry S, Batten L, Dodson A, Martins V, Modi A, Cornman C, Puhalla S, Wolmark N, Julian T, Pogue-Geile K, Robidoux A, Provencher L, Boileau JF, Shalaby I, Thirlwell M, Fisher K, Huang Bartlett C, Koehler M, Osborne K, Rimawi M.

Presenter: Mitchell Dowsett

Session Title: General Session 3 — Hall 3

Session Date & Time: Thursday 12-6-2018; 9:30 AM - 11:30 AM

Presentation Time: 9:45 AM

Program Number: GS4-04

Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer.

Vicini FA, Cecchini RS, White JR, Julian TB, Arthur DW, Rabinovitch RA, Kuske RR, Parda DS, Ganz PA, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, Costantino JP, Bear HD, Germaine I, Gustafson G, Grossheim L, Peterson IA, Hudes RS, Curran, Jr. WJ, Wolmark N.

Presenter: Frank A. Vicini

Session Title: General Session 4 — Hall 3

Session Date & Time: Thursday 12-6-2018; 3:15 PM - 5:00 PM

Presentation Time: 4:00 PM

Abstracts to be Presented at 41st Annual SABCS — December 4-8, 2018

THURSDAY December 6, 2018 con't

Program Number: P3-10-04

The fully validated NSABP/NRG 8-gene signature which predicted the degree of benefit in the adjuvant setting (B-31 and NCCTG N9831) associates with pCR in the neoadjuvant setting in NSABP clinical trial FB-7. (*NSABP Foundation*)

Pogue-Geile KL, Wang Y, Srinivasan A, Gavin PG, Kim RS, Song N, Feng H, Lipchik C, Costantino JP, Wolmark N, Lucas PC, Paik S, Jacobs SA.

Presenter: Katherine L. Pogue-Geile

Session Title: Prognostic and Predictive Factors: Predictive Biomarkers for Targeted Therapies

Location: Poster Session 2 – Hall 1

Session Date & Time: Thursday, 12-6-2018; 7:00 AM - 9:00 AM

Program Number: OT2-04-01

Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC): *NRG Oncology/NSABP B-51/RTOG 1304.*

Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Paik S, Gupta N, Li XA, DiCostanzo DJ, Curran WJ, Wolmark N.

Presenter: Eleftherios P Mamounas

Session Title: Ongoing Trials - Radiation Therapy

Location: Ongoing Trials Poster Session OT2 – Hall 1

Session Date & Time: Thursday, 12-6-2018; 5:00 PM - 7:00 PM

FRIDAY December 7, 2018

Program Number: OT3-05-01

A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze. (*NSABP Foundation - Industry - Genetech-Roche*)

R Geyer, Jr. CE, Loibl S, Rastogi P, Seiler S, Costantino JP, Nekljudova VN, Cortazar P, Lucas PC, Denkert C, Mamounas EP, Jackisch C, Wolmark N.

Presenter: Charles E. Geyer, Jr

Session Title: Ongoing Trials - Targeted- PD-L1

Location: Ongoing Trials Poster Session OT3 – Hall 1

Session Date & Time: Friday, 12-7-2018; 5:00 PM - 7:00 PM